Red Star Capital Bureau reported on January 31 that Haohai Bioscience (688366., one of the three musketeers of medical cosmetologySH) has announced its 2023 earnings forecast.
According to the preliminary calculation of the financial department, the annual net profit in 2023 is expected to be 400 million yuan to 4300 million yuan, a year-on-year increase of 12164% to 13827%；The non-net profit after deduction is about 3$6.7 billion to $39.7 billion yuan, a year-on-year increase of 13118% to 15008%。
Due to factors such as the stagnation of the production and operation of subsidiaries in 2022, Haohaishengke's net profit fell sharply by 48 percent year-on-year76%, which also gives Haohaishengke a large growth space in 2023.
It is worth noting that although the revenue of hyaluronic acid products has increased, the ophthalmology sector, which is the company's main business, is continuing to decline after the inclusion of intraocular lenses and OK lenses in centralized procurement.
The decline will stop in 2023.
Net profit increased by more than 120% year-on-year.
Regarding the growth performance in 2023, Haohaisheng has not elaborated too much for the time being, and mentioned more in 2022.
Haohaisheng said that the company and its manufacturing subsidiary in the Shanghai area were stagnant between March and May 2022, and in 2022, the company made a purchase of its U.S. subsidiary Aaren Scientific IncThe goodwill of the business and the asset impairment loss on intangible assets both had a material adverse impact on the Company's operating income and profit in 2022.
With the stability of the external business environment, the production, operation and sales of the company and its subsidiaries have recovered steadily and continued to improve, and the sales volume and revenue of various product lines, especially hyaluronic acid products, have increased significantly compared with the same period last year. ”
In short, Haohaishengke's net profit in 2023 will increase significantly year-on-year, which is due to the low base in 2022.
In 2022, affected by the stagnation of the above-mentioned subsidiaries, the loss will be about 37.35 million yuan; The goodwill, intangible assets and other long-term assets of the U.S. subsidiary's business provided for a total asset impairment loss of about 46.07 million yuan.
In addition, Red Star Capital Bureau noted that in 2022, due to the implementation of the equity incentive plan, Haohai Biotech and its subsidiary Ouhua Meike will confirm a total of about 30.23 million yuan in share payment expenses; In 2021, the Group received a total of about 56.22 million yuan in dividends from the "Shenwu No. 1" investment product, while no similar dividend income was received and recognized in 2022.
Under the influence of various factors, in 2022, Haohaishengke's net profit will be about 1800 million yuan, a sharp decrease of 48 percent year-on-year76%。
Ophthalmic products are under pressure due to centralized procurement.
Although Haohaisheng is more concerned about medical beauty, in terms of product lines, the proportion of revenue from its ophthalmic products is higher before 2023. The performance of this important sector will also fluctuate in 2023 due to centralized purchasing.
Since its listing, Haohaishengke's main ophthalmic intraocular lens series products have successively won the bid in the procurement of high-value intraocular lens consumables in Beijing-Tianjin-Hebei "3+N", the inter-provincial alliance of ten provinces led by Yunnan Province and Shaanxi Province, Henan Province and other provinces and alliances.
In order to reduce inventory, Haohaishengke distributors' willingness to purchase products has declined. It can be seen that the revenue and proportion of intraocular lenses are continuing to decline.
From 2019 to 2022, Haohaishengke's intraocular lenses achieved revenue of about 43.4 billion yuan, 33.1 billion yuan, 33.3 billion and 27.9 billion yuan. From the perspective of the entire ophthalmic product segment, the proportions of total revenue are: 34% and 3642%。
In addition, in April 2023, Hebei Province led the announcement of the centralized procurement of 19 kinds of medical consumables of the Sanming Procurement Alliance, and OK lenses (i.e., orthokeratology lenses) were officially included in the centralized procurement, which is also one of the businesses of Haohaishengke.
Specifically, Haohaishengke's myopia prevention and control and refractive correction product line is mainly divided into two parts, one is optometric materials, and the other is optometric terminal products. Among them, the optometry terminal products cover orthokeratology lenses and their fitting, equipment used in the wearing process and eye moisturizer products, soft glasses, phakic refractive lenses and other products.
Starting from 2021, Haohaishengke's optometry terminal products have achieved revenue and will grow rapidly in 2022. From 2021 to 2022, the income of this part is 551880,000 yuan and 19.8 billion yuan.
According to the 2022 annual report, the company's myopia prevention and control and refractive correction product lines achieved a total revenue of about 3800 million yuan, a year-on-year increase of 7433%。Among them, the optometric materials business in the upstream of the ** chain increased by 1122%, the optometric terminal products represented by orthokeratology lenses have increased significantly, which said that it is mainly because Nanpeng Optics, which operates the sales business of orthokeratology lenses, has been included in the company's consolidated statements since January 2022.
Entering the first half of 2023, the revenue of optometry terminal products began to decline. As of the first half of 2023, the revenue of this part is 9568750,000 yuan, down 3 percent year-on-year81%。In this regard, Haohaishengke said that it was mainly because the group no longer included Hebei Xinshikang in the scope of merger after the 60% equity of Hebei Xinshikang, a non-wholly-owned subsidiary, on July 1, 2022.
At the same time, the revenue of medical cosmetology and wound care products dominated by hyaluronic acid accounted for (37.).03%) also surpassed ophthalmic products (36.) for the first time7%), becoming the company's highest revenue segment.
Red Star News reporter Deng Lingyao.
Edited by Yu Dongmei.
*Red Star News, Newspaper Rewards! ）